Remarkable shrinkage of a growth hormone (GH)-secreting macroadenoma induced by somatostatin analogue administration: A case report and literature review

Abstract

Acromegaly is caused by excessive growth hormone secretion, usually from pituitary adenomas. Somoato-statin analogues are widely used as primary or adjunctive therapy in the management of acromegaly. In this report, we present a case with remarkable shrinkage of a tumor after relatively short-term octreotide long-acting release (LAR) administration. During the 30-month follow-up after starting octreotide LAR, there was no recurrence of acromegaly with remarkable shrinkage of the tumor on pituitary magnetic resonance imaging. A literature review of the predictors for tumor shrinkage after the administration of somatostatin analogues in patients with acromegaly is also discussed in relation to this case.